+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 8 Actively Recruiting clinical trials

P

Actively Recruiting

Researchers are evaluating the efficacy and safety of SPH5030 tablets in adults with Her2-positive or Her2-mutated biliary tract or colorectal cancer. This phase II clinical study focuses on patients with metastatic, unresectable, or advanced forms of these cancers who have specific genetic markers and meet certain health criteria. The study is sponsored by Shanghai Pharmaceuticals Holding Co., Ltd and aims to better understand treatment outcomes in this group. Participants will receive SPH5030 tablets orally once daily at a dose of 600 mg. The study is open-label and single-arm, meaning all participants receive the same treatment without a placebo group. The treatment period and follow-up span approximately two years, during which multiple outcome measures will be assessed. During the study, participants will undergo regular evaluations to monitor tumor response, duration of remission, disease control, progression-free survival, overall survival, and any adverse events related to treatment. Researchers will also assess safety through clinical and laboratory tests. The total involvement for each participant is about two years, allowing for detailed observation of treatment effects and tolerability.

Age: 18Years +All GendersPhase 2
30 locations
P

Actively Recruiting

Researchers are evaluating the effectiveness of early treatment with BXOS110 injection in reducing disability for patients who have had an acute ischaemic stroke. This phase 3 clinical trial compares BXOS110 to a placebo to better understand its safety and impact when given within three hours of stroke onset. The study includes adults aged 18 to 85 diagnosed with acute ischaemic stroke, with specific neurological and functional criteria for participation. Participants are randomly assigned to one of two groups one receiving a single intravenous infusion of BXOS110 at a dose of 3.0 mgkg up to 300 mg, and the other receiving a placebo infusion of the same volume and dose schedule. The study is double-blind and placebo-controlled, meaning neither participants nor researchers know which treatment is given. The trial consists of a screening and baseline phase, a treatment phase with immediate administration of the study drug, followed by a follow-up period with evaluations on days 2, 3, 10 or at discharge, day 30, and day 90 after treatment. Throughout the study, participants undergo assessments to measure disability and neurological function, including the modified Rankin Scale mRS, NIH Stroke Scale NIHSS, Barthel Index BI, and EQ-5D quality of life questionnaire. The main outcome measured is the proportion of patients achieving an mRS score of 0 to 2 on day 90, indicating good recovery. Safety and efficacy are monitored closely during follow-up visits and at discharge. The total study duration includes screening, treatment, and a 90-day follow-up period to assess outcomes and safety.

Age: 18Years - 85YearsAll GendersPhase 3
9 locations
E

Actively Recruiting

Researchers are evaluating the efficacy and safety of AZD6234 in adults who have obesity or are overweight with at least one weight-related health condition but do not have type 2 diabetes. This Phase III study is randomized, double-blind, and conducted across multiple centers worldwide. Participants will be assigned to receive either AZD6234 or a placebo to compare changes in body weight over 68 weeks of treatment. The study treatments involve subcutaneous injections once a week. Participants will receive one of two doses of AZD6234 or a matching placebo. The trial aims to assess how these treatments affect body weight, waist circumference, triglycerides, blood pressure, and fat mass, including measurements by DXA scans in a subset of participants. The treatment period lasts 68 weeks. During the study, participants will have regular visits for assessments including body weight, waist circumference, blood pressure, and blood tests. Some will have DXA scans to measure fat mass. Researchers will monitor safety and track the percentage change in body weight from the start of treatment. The total participation duration includes 68 weeks of treatment with monitoring at specified intervals.

Age: 18Years +All GendersPhase 3
220 locations
E

Actively Recruiting

Researchers are studying berobenatide to evaluate its safety and effectiveness in adults in China who have overweight or obesity. This study compares berobenatide with a placebo, which looks like the study treatment but does not contain active medicine. Participants may include adults with obesity or those with overweight and certain weight-related health conditions, some of whom may also have type 2 diabetes. Participants will be randomly assigned to receive either berobenatide or placebo once weekly. Those receiving berobenatide will go through a dose-escalation phase followed by a maintenance phase with low, medium, or high doses. The placebo group will receive matching injections once weekly throughout both phases. The study will carefully monitor treatment effects and changes during these periods. During the study, participants will attend visits and complete assessments to track body weight, overall health, and safety. Researchers will collect data on many health measures, including body weight changes, waist size, blood pressure, cholesterol, blood sugar levels, and quality of life. Safety monitoring will continue up to 58 weeks. The main outcome is the percent change in body weight from baseline to week 48, with additional health and safety measures also evaluated.

Age: 18Years +All GendersPhase 3
34 locations
P

Actively Recruiting

Researchers are evaluating the safety and effectiveness of LT3001 for treating acute ischemic stroke. This phase II multicenter study compares LT3001 at high and low doses to a placebo, aiming to understand how well LT3001 works and how safe it is for patients who have suffered this type of stroke. The study is led by Shanghai Pharmaceuticals Holding Co., Ltd and involves participants aged 18 to 80 years. Participants will receive LT3001 or placebo through intravenous infusion. The study uses a randomized, double-blind, placebo-controlled design with parallel groups. Treatment must begin within 24 hours after stroke onset. The trial evaluates multiple outcomes, including stroke severity and daily living abilities at various time points up to 90 days after the first dose. During the study, participants will undergo neurological assessments using scales like the NIH Stroke Scale, Modified Rankin Scale, and Barthel Index at several days after treatment. The main safety measure is the occurrence of adverse events, monitored for about two years. Participants will be closely followed to assess recovery progress and any side effects over time.

Age: 18Years - 80YearsAll GendersPhase 2
28 locations
P

Actively Recruiting

Researchers are evaluating the effectiveness and safety of the KPCXM18 injection at different doses for treating acute ischemic stroke. This phase 2 clinical trial uses a multicenter, randomized, double-blind, parallel, placebo-controlled design to compare treatments. The goal is to provide evidence for future studies and understand how the drug behaves in the body through population pharmacokinetic analysis. Participants are assigned to one of three groups a low-dose KPCXM18 injection group receiving 60 mg twice daily, a high-dose group receiving 100 mg twice daily, or a placebo group. All treatments are given by intravenous infusion every 12 hours for about 12 days. Researchers will observe and compare the effects of these doses against placebo to assess benefits and safety. During the study, participants will be monitored closely with assessments including the Modified Rankin Scale to measure disability at days 12, 30, and 90. Additional evaluations include stroke severity using the NIH Stroke Scale and daily functioning by the Barthel Index. The trial spans about three months of follow-up after treatment, with safety and effectiveness tracked throughout. Participants will be involved in regular visits to measure their recovery progress and any side effects.

Age: 18Years - 80YearsAll GendersPhase 2
23 locations
S

Actively Recruiting

Gastric cancer is a significant health challenge worldwide, and this research aims to develop a new Artificial Intelligence AI system to predict how well tumors respond to combined chemotherapy and immunotherapy before surgery. The study focuses on patients with locally advanced gastric cancer receiving standard neoadjuvant chemo-immunotherapy. The goal is to create a tool that helps doctors personalize treatment plans by predicting tumor response more accurately. Participants will receive standard neoadjuvant chemotherapy combined with approved PD-1 inhibitors, chosen by their treating physician, in a real-world clinical setting. Researchers will collect preoperative contrast-enhanced CT scans, pathological tissue slides, and biological samples like blood and tumor tissue. These will be analyzed using advanced deep learning methods to build and validate a multimodal AI model predicting pathological complete response. During the study, patients will undergo baseline assessments and postoperative pathological evaluations about five months apart. Researchers will monitor the accuracy of the AI model in predicting tumor response, including the rate of complete tumor disappearance after surgery. They will also track disease-free survival for up to three years. The study involves collecting imaging, tissue, and blood samples, as well as clinical data, to support AI development and patient monitoring throughout the treatment process.

Age: 18Years +All Genders
9 locations
E

Actively Recruiting

Researchers are evaluating the effect, safety, and cost-effectiveness of low-sodium salt substitutes in reducing blood pressure and preventing hypertensive disorders in pregnant women at high risk in China. This study will enroll about 3,200 pregnant women at or before 16 weeks of gestation from multiple hospitals across several provinces. The trial uses an adaptive two-phase design, with an interim analysis after the first 400 participants to decide on continuation and sample size adjustments. Participants will be randomly assigned in equal groups to either use a potassium-enriched salt substitute containing 25% potassium chloride and 75% sodium chloride or continue using usual salt with over 99% sodium chloride. The assigned salt will be provided free of charge and used for home-prepared meals until delivery. Follow-up will continue through all antenatal visits and delivery to collect blood pressure data and monitor the incidence of hypertensive disorders and related adverse events. Participants will attend regular antenatal check-ups where blood pressure and other health data will be collected. The primary outcomes include the change in systolic blood pressure from baseline to about 36-37 weeks gestation and the incidence of new hypertensive disorders and maternal adverse events from randomization to delivery. Researchers will also assess safety, adherence, and cost-effectiveness during the study, which continues until delivery for each participant.

Age: 18Years +FEMALEPhase Not Applicable
110 locations